Aton Group: Towards a Reduction of Clinical Failures in Pharmaceuticals

The Aton Group, listed on Euronext Growth Paris, is strengthening its transformation strategy focused on preclinical development. Faced with a 90% failure rate for molecules in clinical trials, the pharmaceutical sector must reassess its experimental models. Aton is banking on intelligent preclinical development to meet this structural challenge.

The group prioritizes the integration of human physiology into its models, thereby increasing predictability and reducing clinical risk from the outset of development. By combining translational pharmacology, human models, and systems analysis, Aton aims to create a unique value chain for its partners.

Aton is actively engaged in discussions with industry players to integrate its innovative solutions, hoping to leverage its assets and optimize resource allocation. Upcoming communications will focus on the reliability of in vitro diagnostics.